Rosetta Genomics Ltd. (ROSGQ)
OTC PINK OTC PINK Primary Summary
ROSGQ Chart
Rosetta Genomics Ltd. (ROSGQ) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Rosetta Genomics Ltd. ever had a stock split?
Rosetta Genomics Ltd. Profile
| Professional Services Industry | Industrials Sector | Douglas Sites CEO | OTC PINK Exchange | IL0011026494 ISIN |
| IL Country | 86 Employees | - Last Dividend | 15 May 2012 Last Split | 27 Feb 2007 IPO Date |
Overview
Rosetta Genomics Ltd. is a global leader in the field of genomic diagnostics, leveraging cutting-edge microRNA technology to provide a range of diagnostic tests designed to enhance patient care in oncology and other areas. Founded in 2000 and based in Rehovot, Israel, the company offers innovative diagnostic solutions to a variety of specialists including oncologists, urologists, endocrinologists, and cytopathologists. Through its advanced tests, it aims to facilitate accurate diagnosis and targeted treatment options for patients. Rosetta Genomics maintains a strong research and development foundation through license agreements and collaborations, such as with Max Planck Innovation GmbH for proprietary microRNA diagnostics and research, and Meir Medical Center for the development of a microRNA classifier for non-small cell lung cancer patients.
Products and Services
- RosettaGX Cancer Origin
- mi-KIDNEY
- RosettaGX Reveal
- mi-LUNG Diagnostic Tests
- UroVysion
- ERG/PTEN FISH-based Prognostic Tests
- ALK/ROS1 Predictive Tests
- PCR Gene Mutation Analysis
Designed to identify the primary site of metastatic cancers, this diagnostic test utilizes the company's sophisticated microRNA technology to provide clear, actionable insights for patient management.
A kidney tumor classification test applied to pathology samples, mi-KIDNEY aids in the precise classification of kidney tumors, which is crucial for choosing the most appropriate treatment pathway.
This diagnostic tool is utilized for the analysis of indeterminate thyroid fine-needle aspirate samples, offering a non-surgical approach to diagnosing thyroid nodules and thereby facilitating appropriate patient treatment plans.
Designed for lung cancer diagnosis, mi-LUNG tests help in identifying specific lung cancer types, enabling personalized treatment strategies for patients diagnosed with lung cancer.
A urine-based Fluorescence In Situ Hybridization (FISH) assay, UroVysion is intended as an aid for the initial diagnosis of bladder carcinoma in patients presenting with hematuria and for monitoring tumor recurrence in individuals previously diagnosed with bladder cancer. It is intended to complement, not replace, current standard diagnostic procedures.
In prostate cancer, these FISH-based prognostic tests are used to help predict disease progression, thereby guiding treatment decisions and patient management strategies.
Indicated for patients diagnosed with advanced stage lung cancer, ALK/ROS1 tests are FISH-based predictive tests that help identify patients who may benefit from targeted therapies, particularly in cases of non-small cell lung cancer.
This suite of tests provides gene mutation analysis for patients with bladder, lung, colon, and melanoma cancers. PCR gene mutation analysis is crucial for identifying targeted therapies and personalizing patient treatment plans.
